Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia. Issue 3 (22nd December 2015)

• Record Type: Journal Article
• Authors: Vendetti, Neika; Bryan, Matthew; Zaoutis, Theoklis E.; Damianos, Andreas; Fisher, Brian T.
• Is Part Of: Mycoses. Volume 59:Issue 3(2016)
• Page Start: 173
• Page End: 178
• Publication Date: 2015-12-22
• Subjects: Candidaemia -- antifungals -- paediatric -- comparative effectiveness; Pathogenic fungi -- Periodicals; Medical mycology -- Periodicals; 616.969
• DOI: 10.1111/myc.12449
• Languages: English
• ISSNs: 0933-7407

Abstract

Summary: Adult data suggest that echinocandins for treatment of candidaemia are associated with decreased mortality, attributed to their fungicidal activity. There are limited data comparing antifungals in children. We compared 30‐day all‐cause mortality among paediatric candidaemia patients treated with fungicidal vs. fungistatic agents. All inpatients (>6 months and <19 years of age) with candidaemia between 2000 and 2012 at The Children's Hospital of Philadelphia were retrospectively identified. Definitive therapy with fungicidal (amphotericin B and caspofungin) agents was compared with fungistatic (fluconazole) agents. A propensity score model generated the inverse probability of receiving a fungicidal agent, which was included in a weighted logistic regression model. Among 203 children meeting inclusion criteria, 151 (74.4%) and 52 (25.6%) received a fungicidal and fungistatic agent, respectively. Overall, 18 (8.9%) patients died within 30 days. There was no statistically significant difference in mortality between patients started on a fungicidal or fungistatic agent (OR: 2.19, 95% CI: 0.42–11.48). In a propensity score–weighted model, definitive therapy with a fungicidal agent did not result in a significant decrease in mortality. These data suggest that both agents can be considered definitive therapy for paediatric candidaemia. The results should be interpreted with caution given the small sample size. Larger cohort studies are needed.